ICLR (ICON plc)
All Pro Portfolios with ICLR
All Do-It-Yourself Portfolios with ICLR
- Total Do-It-Yourself Portfolios with ICLR:
- SINLetter Model Portfolio
- RayTaylor Portfolio 1
- E. Lefevre 1
- Cons
- remrem4 Portfolio 1
- jasonkeith Portfolio 1
- Investors Bus Select portfolio
- Trobadour 1
- tomtom28731 Portfolio 1
- Stockerblog.com Irish Stocks
- SUPRATRADE 2107070150
- SUPRATRADE MODEL TEST
- marlon bizerra Portfolio 1
- Whar-Barton Capital II
- aimei Portfolio 2
- william eng Portfolio 1
- My 6 Slick Picks
- Pharma1
- Lars
- RHM's Stocks
- PART 1 JPMorgan 27th Annual Healthcare Conf 1/12/09..1st Day Reporting Companies..Nymph Take
- show more
- 42
- gus
- JaydeeG's winning Picks!
- Fred Green Portfolio 1
- The Big Bucks
- fiedler556dos2
- yooseok Portfolio 1
- HungryJoe Watch1
- aplusvending4u@yahoo.com Portfolio 1
- Vrible Portfolio 1
- jamaica
- Stiff8 Portfolio 1
- arun07_test
- SUPRATRADE RAPTOR-1909070010
- william 1
- BENITRANS FV
- raleman Portfolio 1
- lilylinmin
- UptrendEarningsBrokers
- chuckd72 Portfolio 1
- MMB
- Fast Money's Healthcare Reform Stock Plays
- News For Selected Stock
- Related stories on theStreet.com
- videos related to etf's
- No videos found
- blogs related to etf's
- No blogs found
Why I Love This Stock |
|
By:barrons3 |
Date:07 08 09 |
According to Windley, the other major shift sees big pharma seeking a cheaping way to produce drugs through outsourcing. On this point, he said he would go with drug development companies such as Paraexel (PRXL) and Icon (ICLR). |
|
Not yet rated
Rate now:
|
|
By:lilylinmin |
Date:11 20 07 |
medical and clinical service, healthy backlog |
|
Not yet rated
Rate now:
|
|
Date:10 11 07 |
|
High earnings growth |
|
Not yet rated
Rate now:
|
|
By:stockerblog |
Date:06 25 07 |
P/E of 29, a PEG of 1.25, and a P/S of 2.5. |
|
Not yet rated
Rate now:
|
|
By:fafuan |
Date:05 28 07 |
Low Price to sales vs peers |
|
Not yet rated
Rate now:
|
|
By:HungryJoe |
Date:05 18 07 |
another pharma outsourcing play (see CVD) |
|
Not yet rated
Rate now:
|
|
By:Lars |
Date:02 03 07 |
IBD article. Projected 40% earnings growth. |
|
Not yet rated
Rate now:
|
|
Date:01 28 07 |
|
Pharma Services - Ireland. Company with expertise in the management, execution and analysis of complex multinational clinical trials. Demand for these services are evermore important |
|
Not yet rated
Rate now:
|
|
By:galenbrooks |
Date:01 03 07 |
growth |
|
Not yet rated
Rate now:
|
|
Why I Hate This Stock |
|
| Comments not available |
